{"id":55638,"date":"2023-04-10T14:06:31","date_gmt":"2023-04-10T12:06:31","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/apnimed-to-present-at-the-22nd-annual-needham-virtual-healthcare-conference\/"},"modified":"2023-04-10T14:06:31","modified_gmt":"2023-04-10T12:06:31","slug":"apnimed-to-present-at-the-22nd-annual-needham-virtual-healthcare-conference","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/apnimed-to-present-at-the-22nd-annual-needham-virtual-healthcare-conference\/","title":{"rendered":"Apnimed to Present at the 22nd Annual Needham Virtual Healthcare Conference"},"content":{"rendered":"
\n

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep apnea (OSA) and related disorders, including its lead oral treatment candidate AD109, today announced that Company management will present and host one-on-one investor meetings at the 22nd<\/sup> Needham Healthcare Conference taking place virtually April 17-20, 2023.<\/p>\n

<\/a><\/p>\n

\nPresentation Details<\/b><\/p>\n

\nThe corporate presentation will be on April 17, 2023, from 9:30 -10:10 am ET in Track 2. The webcast presentation replay will be available for viewing on the News and Events<\/a> section of the Company’s website.<\/p>\n

\nOne-on-one meeting schedules will be accessible to registered conference attendees.<\/p>\n

\nAbout AD109<\/b><\/p>\n

\nAD109 has the potential to be the first oral pharmacologic that both treats the underlying cause of OSA, airway obstruction at night, and improves daytime consequences of OSA such as fatigue. It is a potential first-in-class, novel, investigational combination dosed once daily at bedtime, designed to treat OSA patients across a broad spectrum of disease severity. AD109 combines Apnimed\u2019s novel selective antimuscarinic (aroxybutynin) with a selective norepinephrine reuptake inhibitor (atomoxetine). AD109 targets key neurological pathways in OSA that activate upper airway dilator muscles to maintain an open airway during sleep. AD109 has the potential to become a safe, effective, and convenient treatment for OSA, addressing some of the key limitations of current standard of care treatments that can be poorly tolerated (e.g., CPAP) and\/or invasive (e.g., surgery or implanted devices).<\/p>\n

\nAD109 has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA).<\/p>\n

\nAbout Obstructive Sleep Apnea<\/b><\/p>\n

\nObstructive Sleep Apnea is one of the most common and serious sleep disorders. It is estimated to affect more than 35 million Americans, though underdiagnosis continues to be a serious problem and the number of affected Americans may be far greater. OSA is characterized by partial or complete upper airway obstruction that occurs during sleep, which often leads to poor sleep, and in the long term, has been shown to exacerbate hypertension, diabetes, cardiovascular disease, and stroke. Additionally, OSA can impair work productivity, reduce daytime functional abilities, and lower quality of life. Sleep-related muscular relaxation driven by the central nervous system is the key neurologic mechanism that causes OSA. In patients with OSA, a reduction in neuromuscular control of the upper airway during sleep leads to a corresponding relaxation of the upper airway dilator muscles. The vast majority of diagnosed patients are prescribed positive air pressure therapy devices such as continuous positive airway pressure, or CPAP, but many patients are dissatisfied with these mechanical nighttime devices and fewer than half are compliant long term, leaving a significant population untreated, undertreated and at risk.<\/p>\n

\nAbout Apnimed<\/b><\/p>\n

\nApnimed is a clinical-stage pharmaceutical company working to transform the treatment of sleep apnea based on a simple idea \u2013 patients with obstructive sleep apnea could benefit from treatment with a safe and effective oral medication dosed once daily at bedtime. Apnimed\u2019s lead development program targets the neurologic control of upper airway muscles to maintain an open airway during sleep. Based in Cambridge, Mass., the company is developing a portfolio of novel pharmacologic therapies for sleep apnea and related disorders. Learn more at apnimed.com<\/a> or follow us on Twitter<\/a> and LinkedIn<\/a>.<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia:<\/strong>
Courtney Heath
\n
ScientPR
\n
courtney@scientpr.com<\/a><\/p>\n

\nInvestor:<\/strong>
Wendy Gabel
\n
Kendall Investor Relations
\n
wgabel@kendallir.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep apnea (OSA) and related disorders, including its lead oral treatment candidate AD109, today announced that Company management will present and host one-on-one investor meetings at the 22nd Needham Healthcare Conference taking place virtually April 17-20, … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-55638","6":"format-standard","7":"category-industry"},"yoast_head":"\nApnimed to Present at the 22nd Annual Needham Virtual Healthcare Conference - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/apnimed-to-present-at-the-22nd-annual-needham-virtual-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Apnimed to Present at the 22nd Annual Needham Virtual Healthcare Conference - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass.–(BUSINESS WIRE)–Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep apnea (OSA) and related disorders, including its lead oral treatment candidate AD109, today announced that Company management will present and host one-on-one investor meetings at the 22nd Needham Healthcare Conference taking place virtually April 17-20, ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/apnimed-to-present-at-the-22nd-annual-needham-virtual-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-10T12:06:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230410005068\/en\/1758952\/21\/Apnimed_logo_%281%29.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/apnimed-to-present-at-the-22nd-annual-needham-virtual-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/apnimed-to-present-at-the-22nd-annual-needham-virtual-healthcare-conference\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Apnimed to Present at the 22nd Annual Needham Virtual Healthcare Conference\",\"datePublished\":\"2023-04-10T12:06:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/apnimed-to-present-at-the-22nd-annual-needham-virtual-healthcare-conference\\\/\"},\"wordCount\":563,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/apnimed-to-present-at-the-22nd-annual-needham-virtual-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230410005068\\\/en\\\/1758952\\\/21\\\/Apnimed_logo_%281%29.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/apnimed-to-present-at-the-22nd-annual-needham-virtual-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/apnimed-to-present-at-the-22nd-annual-needham-virtual-healthcare-conference\\\/\",\"name\":\"Apnimed to Present at the 22nd Annual Needham Virtual Healthcare Conference - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/apnimed-to-present-at-the-22nd-annual-needham-virtual-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/apnimed-to-present-at-the-22nd-annual-needham-virtual-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230410005068\\\/en\\\/1758952\\\/21\\\/Apnimed_logo_%281%29.jpg\",\"datePublished\":\"2023-04-10T12:06:31+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/apnimed-to-present-at-the-22nd-annual-needham-virtual-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/apnimed-to-present-at-the-22nd-annual-needham-virtual-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/apnimed-to-present-at-the-22nd-annual-needham-virtual-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230410005068\\\/en\\\/1758952\\\/21\\\/Apnimed_logo_%281%29.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230410005068\\\/en\\\/1758952\\\/21\\\/Apnimed_logo_%281%29.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/apnimed-to-present-at-the-22nd-annual-needham-virtual-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Apnimed to Present at the 22nd Annual Needham Virtual Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Apnimed to Present at the 22nd Annual Needham Virtual Healthcare Conference - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/apnimed-to-present-at-the-22nd-annual-needham-virtual-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"Apnimed to Present at the 22nd Annual Needham Virtual Healthcare Conference - Pharma Trend","og_description":"CAMBRIDGE, Mass.–(BUSINESS WIRE)–Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep apnea (OSA) and related disorders, including its lead oral treatment candidate AD109, today announced that Company management will present and host one-on-one investor meetings at the 22nd Needham Healthcare Conference taking place virtually April 17-20, ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/apnimed-to-present-at-the-22nd-annual-needham-virtual-healthcare-conference\/","og_site_name":"Pharma Trend","article_published_time":"2023-04-10T12:06:31+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230410005068\/en\/1758952\/21\/Apnimed_logo_%281%29.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/apnimed-to-present-at-the-22nd-annual-needham-virtual-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/apnimed-to-present-at-the-22nd-annual-needham-virtual-healthcare-conference\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Apnimed to Present at the 22nd Annual Needham Virtual Healthcare Conference","datePublished":"2023-04-10T12:06:31+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/apnimed-to-present-at-the-22nd-annual-needham-virtual-healthcare-conference\/"},"wordCount":563,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/apnimed-to-present-at-the-22nd-annual-needham-virtual-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230410005068\/en\/1758952\/21\/Apnimed_logo_%281%29.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/apnimed-to-present-at-the-22nd-annual-needham-virtual-healthcare-conference\/","url":"https:\/\/pharma-trend.com\/en\/apnimed-to-present-at-the-22nd-annual-needham-virtual-healthcare-conference\/","name":"Apnimed to Present at the 22nd Annual Needham Virtual Healthcare Conference - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/apnimed-to-present-at-the-22nd-annual-needham-virtual-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/apnimed-to-present-at-the-22nd-annual-needham-virtual-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230410005068\/en\/1758952\/21\/Apnimed_logo_%281%29.jpg","datePublished":"2023-04-10T12:06:31+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/apnimed-to-present-at-the-22nd-annual-needham-virtual-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/apnimed-to-present-at-the-22nd-annual-needham-virtual-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/apnimed-to-present-at-the-22nd-annual-needham-virtual-healthcare-conference\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230410005068\/en\/1758952\/21\/Apnimed_logo_%281%29.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230410005068\/en\/1758952\/21\/Apnimed_logo_%281%29.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/apnimed-to-present-at-the-22nd-annual-needham-virtual-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Apnimed to Present at the 22nd Annual Needham Virtual Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55638","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=55638"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55638\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=55638"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=55638"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=55638"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}